Startups 

Infertility affects millions of families worldwide. Around 1 in 6 couples experience difficulties when trying to conceive, and nearly 50% of women describe infertility as the most stressful experience of their lives. While IVF treatment offers hope, it can be emotionally demanding, physically challenging, and financially burdensome—especially when multiple cycles are required to achieve pregnancy. 

Fertiga was founded to improve this experience and increase success rates from the very first IVF attempt. As a spin-off from Brussels IVF, Fertiga builds on strong scientific and clinical expertise in reproductive medicine. The company focuses on developing innovative molecular diagnostics that support better decision-making during fertility treatment. 

At the core of Fertiga’s technology portfolio is the Aurora Test, a molecular PCR-based solution designed for non-invasive embryo prioritization. The test analyzes specific molecular signals (RNA expression) to help identify the embryo with the highest implantation potential—without harming or disturbing it. It does this through measurement of cumulus cell, cells surrounding the egg, which are discarded during IVF treatment. By providing fertility specialists with more precise information, the Aurora Test aims to increase first-cycle pregnancy success, reduce the number of repeated treatments, and lower the emotional and financial burden for patients. 

Fertiga’s go-to-market strategy initially targets Europe and the Middle East, regions characterized by advanced fertility clinics, growing IVF demand, and supportive healthcare frameworks. The Aurora Test is positioned for integration into routine IVF practice. 

Fertiga is initially entering the market by offering the test as a central service in Brussels. With the development of a diagnostic kit, Fertiga will accelerate international expansion and broaden clinical impact. The ambition is clear: to improve IVF outcomes and bring new hope to future mothers and fathers worldwide.